Is Semaglutide Approved for Weight Loss in the UK?

Step 1: understanding which semaglutide licence actually covers weight loss

This is the question our prescribers hear most weeks, and the confusion is understandable. Semaglutide exists under several brand names in the UK, and they are not interchangeable for weight loss purposes.

Ozempic (also semaglutide) is licensed for type 2 diabetes. Rybelsus is oral semaglutide licensed for type 2 diabetes. Neither of these is approved for weight management, and a prescriber cannot legally issue them for that purpose. The MHRA is clear on this distinction, and it matters when you are assessing whether a source is legitimate.

Wegovy is the brand that holds the weight-loss licence. The injection form was approved first, followed by Wegovy tablets in June 2026. You can read the NHS's plain-language overview of semaglutide on the NHS website, which covers both indications and sets out who the medicine is and is not suitable for. When a page or a seller refers to semaglutide for weight loss without specifying Wegovy specifically, it is worth pausing to verify what exactly is being offered and under what licence.

For a detailed look at how the MHRA approval process unfolded, the Wegovy approval for weight loss page covers the regulatory timeline in full, and our wegovy approved page explains what that approval status means in practice for patients today.

Step 2: who the approved weight-loss licence covers, and the NICE layer on top

The licensed eligibility criteria in the Wegovy SmPC are broad by design. Adults with a BMI of 30 or above qualify, as do adults with a BMI of 27 to 29.9 who also have at least one weight-related condition, for example, high blood pressure, high cholesterol, obstructive sleep apnoea, prediabetes or type 2 diabetes. For people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, UK guidance recognises that lower BMI thresholds (typically 2.5 kg/m² less) can reflect equivalent health risk.

Then there is the NICE layer. NICE's appraisal of Wegovy (technology appraisal TA875) recommends semaglutide injection for NHS use, but within tighter parameters: BMI of 35 or above (or 32.5 for some ethnic backgrounds), at least one weight-related comorbidity, and treatment via a specialist weight management service for a maximum of two years. That is a narrower group than the licensed population, and NHS waiting lists for specialist services are commonly long.

Private prescribing works to the licensed eligibility criteria, not the NICE NHS criteria, so the BMI threshold is lower and there is no specialist-referral requirement. A prescriber still assesses the full clinical picture, BMI alone is never the deciding factor.

If you want to explore your options, the semaglutide weight loss page goes deeper on the evidence behind the treatment.

Step 3: what the trial results behind the approval actually showed

The MHRA approval was based on robust phase 3 evidence. The landmark STEP 1 trial (published in the New England Journal of Medicine) ran for 68 weeks in adults with obesity or overweight and at least one weight-related condition, without diabetes. Participants using 2.4 mg semaglutide weekly alongside lifestyle changes achieved an average body-weight reduction of around 15%. That is a meaningful figure, roughly three times what most lifestyle interventions alone produce in trials of similar length.

The 7.2 mg dose, whose dedicated single-dose pen was approved on 14 April 2026, has shown average weight loss of around 20.7% over 72 weeks in trials, narrowing the gap with tirzepatide at its highest dose. And the oral tablet (approved in June 2026) showed around 13.6% average weight loss over 64 weeks in the OASIS 4 trial, rising to roughly 17% among participants who adhered fully throughout.

These are average figures from controlled trials. Individual results depend on starting weight, lifestyle changes made alongside treatment, and how well the medicine is tolerated. No result is guaranteed. The semaglutide use for weight loss page sets out what the evidence means for real-world expectations.

Step 4: getting a legal prescription, the NHS route and the private route

Because Wegovy is a prescription-only medicine, the only legal route to it is a prescription issued following a clinical assessment. There is no shortcut, and sellers offering semaglutide without one are operating outside UK law. The MHRA has seized large quantities of fake weight-loss pens sold through unverified channels, you can report suspect sellers at the MHRA's Yellow Card site.

On the NHS, access to Wegovy goes through specialist weight management services under TA875 criteria. That process can take time, some patients wait many months. If your payday lands in January and you want to start treatment without a wait, private prescribing through a regulated UK pharmacy is a separate, legal route that does not require a GP referral. If you are based in Scotland, our wegovy glasgow page covers how to access treatment locally.

At nume, every consultation is reviewed the same day by a GPhC-registered Independent Prescriber, a named clinician reads your answers, not software. You can learn more about Wegovy at nume or look at the broader weight-loss treatment options we offer. Our pharmacy's registration is verifiable on the GPhC register (premises number 9012878). If you'd like to check your eligibility, that is a good place to start.